Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I made a post yesterday regarding the requirements to move to the OTCQB.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152603148
The only thing that might be holding SOLI up to file for the OTCQB is a current audited 10K ( again, I am not sure if they need to do this first before filing). If that is the case, we should see the audited 10K by first Q of 2020. And a filing shortly after.
I have full confidence in SOLI management. Look how they keep getting things done.
I do think that we still have limited exposure to SOLI. Although we have had two PRs unless you are familiar with SOLI you might not have reacted to the PRs.
Also, I think that the MAXIS GBN deal is huge but we don't know yet what the revenue impact is. We are at the stage now where people want to see revenue growth leading to being profitable.
Management is executing on all levels and I am confident that more deals will be announced soon.
The ball is just starting to roll and it is picking up momentum.
Less than a year ago we were on the Greys, with a CE, Shell Risk, no Verified TA, no Verified Profile, no CareClix acquisition.
All that has changed in less than a year and now it is full steam ahead.
If CareClix is connected with Medicare/Medicaid it will be a booster rocket for sure.
We shall see.
Shell Risk is gone from SOLI OTC Markets Page!!!!
Management getting things done!!!
otcmarkets.com/stock/SOLI/disclosure
That's an old picture. I shaved the beard off. LOL
LULU looking good.
Earnings 12/11 ( next week ). I expect the calls to continue to appreciate into earnings.
I agree with you EdF. Something bigger will be coming down the pike.
New Furnace Installed and Testing
Press Release | 12/04/2019
Tuesday, December 3, 2019, Draper, UT NRP Stone, Inc. Announces New Furnace Installation and Testing.
The Luxium test lab, now located in Utah, received and installed the test-furnace and specialized equipment used in the test-production of Luxium. After initial testing, due to the furnaces heat, new and specialized crucibles had to be ordered to replace the traditional crucibles that were destroyed in the first attempts of testing, which have been received. NRP has been notified that the furnace is ready to test the new crucibles in the test-production of Luxium Gen1. This test, when scheduled, will precede new formulations for Gen2 Luxium.
NRP due diligence of Rare Metals and Gems Investors, LLC (RMGI), NRPs proposed acquisition, has continued. Due to disagreements between the principals of RMGIs manufacturer, two of the three principals, including the scientist responsible for formulating Gen2 Luxium, are forming a new company that will have their diamond technology and new Luxium product, and NRP has been advised and has confirmed that the formulation and production of the new Luxium metal will belong to them. As a result, RMGI is negotiating new agreements with these principals and the new entity to reside in the new manufacturing entity, for an exclusive marketing arrangement for white and colored diamonds as well as the Gen2 product.
Although full details are not yet available, what has been acknowledged is that these new agreements could have a much greater impact on the future of NRP Stone than a mere marketing agreement as previously sought. RMGI has proposed joint manufacturing operations for both diamonds and the Gen2 metal. A fully-integrated funding, manufacturing, and marketing strategy for a multiple-phased plan of manufacturing and marketing is being discussed and is in contract formation. NRP has been told that once the new diamond entity has been formed by the principals more information will become available.
NRP Stone, Inc. is engaged in marketing and distribution of unique precious metals and gems. SYM: NRPI (NRPI.PK) U.S.: OTC; CUSIP: 62940J200. Website: https://nrpstone.co. Email: davidmclarkii@nrpstone.co. Follow us on Twitter @nrpstone.
LULU new HOD WOW
LULU hitting new HOD!
12/13 Calls are rocking
Just kidding. My 4 kids are great and nice adults.
I'm trying to sell my kids!
Your the man!
I can't wait to see what SOLI has up it's sleeves next.
Now they are in stronger hands. Very nice.
That's ok. Let stronger hands hold the shares now.
The momentum will continue to build as the word gets out about a small company in a red hot industry. Healthcare costs are the number 1 problem, even bigger than college costs.
Telemedicine is a great way to help with healthcare costs.
Here is your keeping the faith: great video/song
8K v.s. PR
I did some reading this morning on issuing an 8k v.s. a PR, or doing both.
Here is a good summary: (BTW although it appears to be somewhat of a judgement call, I trust that SOLI consults with their legal team on when to issue 8k's. SOLI has done everything by the book so far and I don't expect them to change now.)
Form 8-K: a legal requirement for “material” events
While some companies are using vehicles like social media, their IR website, and other online platforms to share news, I want to focus on two primary modes of disclosure — Form 8-K and a news release. First, though, let’s be clear on what Form 8-K is and why it exists. In the most general terms, Form 8-K is an SEC disclosure vehicle used to provide the public with information deemed necessary to make an informed investment decision about a public company. As the SEC explains it, “the types of information required to be disclosed on Form 8-K are generally considered to be ‘material,’” … [meaning] “there is a substantial likelihood that a reasonable investor would consider the information important in making an investment decision.” Certainly, any questions about when and why to file an 8-K should be directed to your corporate counsel, but I’d like to share a few things to consider beforehand and help you understand what constitutes “material.”
Material events include a change in your financials (some people suggest “10 percent” as a general rule) that differs from your previously reported, publicly disclosed guidance and from what the analysts are projecting. They also include a change in an anticipated product launch date that could affect the timing of sales, an important new customer, an FDA decision or significant change to coverage or reimbursement, a change in executive leadership or your board, the decision to enter into a merger or acquisition, or anything else that can substantially affect your business, such as the availability of a new or updated investor presentation on your website.
Form 8-K is a legal filing, and when a “material” event happens, your company is legally bound to submit one. It’s a straightforward form on which you list factual information only. There’s no room to explain how or why the event happened — only that it did happen.
To determine whether you need to submit an 8-K, your management team needs to ask itself this question: does this event affect decisions made by investors, now or in the future? If you answer yes, then you need to file the 8-K.
Arguably, one could say that anything that happens at the company could have an impact on an investor’s decision — and, yes, I have had a client who wanted to play it extra safe by filing a Form 8-K for everything, from the date of an earnings call to the roll out of a new corporate logo. But that isn’t necessary. Again, when in doubt, check with your corporate counsel.
Press release: your chance to add “color” and context
Unlike the straightforward Form 8-K, a press release is a chance for your company to explain the event in the context of your company’s story. In the scenario above regarding the diagnostics company with an over-accrual, we asked: “Is there a qualitative benefit involved?” “Does this affect the ongoing business or result in a change to any prior guidance?” In both cases, the answer was no, and a release would not provide any more “color” as to how and why.
In the event of a material event, ask yourself: is there more to the story to explain than an 8-K allows? Would my shareholders benefit from knowing some of the how and why? If you answer yes, then you’ll likely want to issue a press release.
Consider, for example, a change in your financial guidance. For this, you’ll need to issue an 8-K that incorporates, by reference, a news release that is publicly issued over a major news wire service and explains why the change happened. The news release is your opportunity to include quotes from your management team (which you can’t do in an 8-K) and articulate the context of the change, how this affects your business, and what next steps you may take. This added information constitutes a critical part of the disclosure — the qualitative information.
Of course, press releases can be used to communicate far more than material events, such as announcing the date of your quarterly conference call or spreading the word about all kinds of things — an upcoming speaking engagement for an executive, the new hire of a non-executive, the launch of a new logo or website, or your decision to support a charity or take on a new initiative — all of which have no real impact on operations. These kind of press releases are important because they keep investors updated, validate events you’ve already highlighted in prior disclosures (such as a product launch or anticipated customer agreement), and keep your company top of mind with shareholders.
The gray area: to issue a press release, an 8-K, or both?
In healthcare — as in any business — there are some gray areas that can be hard to navigate. Take, for example, a minor insurance coverage reimbursement decision. In all likelihood, you want to consider the size of the reimbursement (i.e., the number of covered lives) to determine whether the coverage will affect your revenue significantly or if it points to a trend. If a major health carrier decides to reimburse patients who buy your test or product, you’ll want to consider issuing both an 8-K and press release. Likewise, if the major carrier decides against coverage, you’ll need to do the same.
Use your judgment, and always assess the impact on your business and bottom line. If a smalltime private payer decides to cover your implant for its 200 subscribers, then a press release will usually suffice, as the revenue generated won’t make a significant difference. Keep in mind, too, that major carriers like Blue Cross Blue Shield or UnitedHealthcare don’t always allow companies to use their name in a press release, especially if the company is lesser known and small-scale. In this case, an 8-K is your only option.
How you disclose both positive and negative information to the Street is important, and you want to follow the rules set by the SEC’s Regulation FD and come across as transparent and honest.
If your company needs guidance developing a strong communications strategy and optimizing how you disclose news, Westwicke can help. Download our Investor Relations Guide to learn about our approach, and reach out to us to start the conversation.
I read thru the requirements for OTCQB this morning.
SOLI appears to meet all the requirements.
The only thing I am not sure of is if SOLI needs to issue their audited 10K for 2019 first to fully meet the audit requirement since their last audited filing was almost 1 year ago ( for the 2018 filing ).
So I would expect SOLI to file for OTCQB in the first quarter of 2020.
I can live with that!!
It's nice to see SOLI PR now that they are off the greys and the CE is removed.
Onward and upward.
But are you going to buy some SOLI too? LOL
If you look back on how much SOLI has accomplished in the last 9 months it really is amazing:
- became fully audited.
- raised money to acquire CareClix
- acquired CareClix
- won lawsuit and eliminated 12.6 illegal shares
- started to grow the revenue at CareClix from 0 to over $531k last Q
- found a sponsoring Market Maker to file the form 211
- got the form 211 accepted by FINRA
- got the CE removed
- got Greg Arms to work with them as a Senior Advisor
Good for you. Lots of nice buying today and I expect it to continue.
We knew it was coming and we did hit some bumps along the way but I think the worst is behind us.
We are well on our way.
They are everywhere. This deal is huge.
It will happen at some point.
If you are familiar with Telemedicine and want to get in on the ground level what better choice than SOLI.
Great buys going thru now. WOW
Yes this is just the start of a great ride.
This deal is so huge.
The fun part is we don't know yet how much this is going to mean to the revenue.
Was that your buy?
I expect many more deals to be announced.
Greg Arms is there for a reason.
He will use all of his connections.
And this is just the start.
I can't wait to see his next trick...I mean treat.
I would love to get some TDOC longs over here.
Would love to see a PR with both TDOC and SOLI tickers in it.
You got it bdell!
The fun is just starting. SOLI management keeps performing.
Great times ahead.
I just got an email alert about today's news from SOLI IR website.
I can't wait to see the next Greg Arms surprise.
I am sure there are many more to come.
Keep up the good work!!
10-15% per day would be great.